Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation
Viruses · 2024
DOI: 10.3390/v16121854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Aanand Sonawane und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology & Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chennai 600031, India. Hauptthemen laut MEDLINE: HIV-1, Drug Resistance, Viral, Virus Replication, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, institutional funds of ICMR-National Institute for Research in Tuberculosis.
Abstract (Originalsprache)
The biological characteristics of early transmitted/founder (T/F) variants are crucial factors for viral transmission and constitute key determinants for the development of better therapeutics and vaccine strategies. The present study aimed to generate T/F viruses and to characterize their biological properties. For this purpose, we constructed 18 full-length infectious molecular clones (IMCs) of HIV from recently infected infants. All the clones were characterized genotypically through whole genome sequencing and phenotypically for infectivity, replication kinetics, co-receptor usage, as well as their susceptibility to neutralizing antibodies and entry inhibitors using standard virological assays. Genotypic analysis revealed that all the T/F clones were of non-recombinant subtype C, but some of them harboured the Y181C drug resistance mutation associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretroviral drugs. In vitro studies showed that while all the IMCs were capable of replicating in PBMCs and utilized the CCR5 co-receptor for cellular entry, the drug-resistant variants had significantly lower replicative capacity and per particle infectivity than the drug-sensitive viruses. Both exhibited similar sensitivities to a standard panel of broadly neutralizing monoclonal antibodies and viral entry inhibitors. These findings suggest that despite their diminished replicative fitness, the drug-resistant T/F variants retain transmission fitness and remain susceptible to neutralizing antibody-based interventions and viral entry inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology & Biotechnology, ICMR-National Institute for Research in Tuberculosis, Chennai 600031, India.
- Department of Immunology, University of Madras, Chennai 600005, India.
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA.
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hil, NC 27599, USA.
- Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA 30329, USA.
ORCID-Profile: Deepak Selvam, Sandhya Vivekanandan, Manickam Ashokkumar, Eric Hunter
Förderung
- NIAID NIH HHS
- institutional funds of ICMR-National Institute for Research in Tuberculosis
Zitieren
APA
Sonawane, A., Selvam, D., Yue, L., Nesakumar, M., Vivekanandan, S., Ashokkumar, M., Hunter, E., & Hanna, L. E. (2024). Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation. Viruses. https://doi.org/10.3390/v16121854
Vancouver
Sonawane A, Selvam D, Yue L, Nesakumar M, Vivekanandan S, Ashokkumar M, et al. Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation. Viruses. 2024. doi:10.3390/v16121854
BibTeX
@article{Sonawane2024,
author = {Sonawane, Aanand and Selvam, Deepak and Yue, Ling and Nesakumar, Manohar and Vivekanandan, Sandhya and Ashokkumar, Manickam and Hunter, Eric and Hanna, Luke Elizabeth},
title = {Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121854}
}
EUVIMED